Clinical Trial Update: A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study of KT501, given subcutaneously to patients with rheumatoid arthritis, is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• KT501

Snippet

Sponsor: Kali Therapeutics, Inc. | Conditions: Rheumatoid Arthritis (RA) | Phase 1 | Status: RECRUITING